Levetiracetam


S-enantiomer pyrrolidinone (SV2A ligand)

The (S)-enantiomer of etiracetam, FDA-approved as Keppra for partial-onset seizures, characterized by the SV2A synaptic vesicle binding mechanism distinct from classical racetam pharmacology.

Abstract

Levetiracetam (Keppra; (S)-ฮฑ-ethyl-2-oxo-1-pyrrolidineacetamide; CAS 102767-28-2; molecular formula C8H14N2O2; molecular weight 170.21) is the (S)-enantiomer of etiracetam, developed at UCB Pharma and approved by the FDA in 1999 for partial-onset seizures, with subsequent expansion to primary generalized tonic-clonic seizures and myoclonic seizures. The compound is distinct from other racetams in mechanism: levetiracetam binds with high affinity (Kd approximately 1 microM) to synaptic vesicle protein 2A (SV2A), a presynaptic vesicle membrane protein involved in neurotransmitter release regulation. SV2A binding modulates calcium-dependent neurotransmitter release and reduces hypersynchronous neuronal firing in epileptic networks. The compound has minimal effect on classical neurotransmitter receptors. Pharmacokinetics: plasma half-life 6 to 8 hours; oral bioavailability essentially complete; renal excretion with minimal hepatic metabolism. The compound is also studied off-label for cognitive enhancement based on hippocampal hyperactivity attenuation, with mixed results in mild cognitive impairment trials. Schedule status varies; the compound is not scheduled federally in the United States but is prescription-only.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph